



InPharmation

The official publication of the Pharmacy Department
Volume 3, Issue 2

Regulatory

Inside this issue:

P&T Changes, Patient Safety Corner, Regulatory Information, and Cover story continued 2

Staff Spotlight

Brittany Gorden, PharmD

"Be yourself, everyone else is already taken." –Oscar Wilde



Brittany Gorden was born and raised in New Orleans, LA and is one of our new pharmacists. Though she lives in Baton Rouge now, she visits New Orleans every chance she gets. This is no surprise considering how much she loves her family. Brittany is the daughter of two supportive parents and the proud big sister to her two little brothers. Most of her family may be in NOLA, however she does have her fur-baby, Luna, who is a Pembroke Welsh corgi and who she refers to as a total diva with a Napoleon complex.

When asked what Brittany loves about being a pharmacist, she talks about the ability to impact the lives of her patients and being a resource to other health professionals. After pharmacy school, Brittany completed an ambulatory care focused/academic based residency. She enjoys the flexibility and opportunities pharmacy allows in her life. When she isn't working as a pharmacist, her favorite hobby is photography, which is she trying to turn into a side job.

Brittany is a true southern girl as her favorite meal consists of anything with crawfish in it. Her guilty pleasures consist of reality television and social media. If Brittany could change one thing in this world, it would be allowing people to empathize with those different from themselves. She believes if people were able to put themselves in others' shoes, it would solve many of the world's injustices.

Recent FDA Approvals

- **Fluticasone propionate and salmeterol (Airduo Respiclick)** is indicated for the treatment of asthma in patients aged 12 years and older. It is a combination of an inhaled corticosteroid and a long acting beta₂ agonist.
- **Plecanatide (Trulance)** is an oral tablet indicated in adults for the treatment of chronic idiopathic constipation. This medication is in the same class as Linzess.
- **Hydrocodone bitartrate (Vantrela ER)** is an extended-release tablet indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Med Safety Alerts

Due to an increased risk of angioedema, hypotension, acute kidney injury, and hyperkalemia, concomitant use of an angiotensin-converting enzyme inhibitor (ACE) and sacubitril/valsartan (Entresto) should be avoided. 55 cases of concomitant use have been reported to the FDA, some with adverse outcomes. Recommendations to prevent the concomitant use include: alerts in order entry systems, review of patients medication history, patient and caregiver education; and medication reconciliation.

Patient Safety Corner

ISMP Safety Practice Guideline 6: Drug Information Resources

6.1 Standardized, facility-approved IV push medication resources are readily available at the point of care to guide the safe practice of IV push medication administration. Resources should include any special considerations for the preparation and administration of IV push medications and for unique practice locations where medications may be administered IV push to ensure effective patient monitoring.

- This is accomplished at our institution through the use of readily available online drug information resources, but the ISMP points out that instructions regarding drug dilution and IV push administration procedures may be lacking, difficult to find, or variable between resources. It is important to have readily available, point-of-care guidance for IV push medications on the patient's MAR or medication label.

Safety Opportunity

In order to improve patient safety, the American Society for Parenteral and Enteral Nutrition (ASPEN) has adopted a new abbreviation for IV fat emulsion. The previous abbreviation, IVFE, has been confused with IV iron (IVFe) creating the potential for medication errors. In response to this, the FDA has changed the terminology to lipid injectable emulsion with the new abbreviation ILE. ASPEN and OLOL dietitians have adopted this new term and abbreviation to decrease the risk for medication errors with TPNs.

INPHARMATION EDITORIAL STAFF

Editor-in-Chief
Jennifer Jones, PharmD, BCPS

Writing Staff
Laura Carrell, PharmD
Katie Ducote, PharmD, BCPS
Kristin Howell, PharmD

Brandi LaFrance, PharmD, BCPS
An Nguyen, PharmD
Danielle Thomas, PharmD